Business Insider4d
The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
The FDA has announced that popular weight loss medication tirzepatide is no longer in shortage, potentially removing cheaper versions of the drug from the market by early 2025. Tirzepatide is the ...
The American Journal of Managed Care9d
Weight Loss Drug Tirzepatide Now Approved for Sleep Apnea in Adults With Obesity
Tirzepatide is approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, alongside diet and exercise. The SURMOUNT-OSA trial showed significant reductions in breathing ...
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
JD Supra10d
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked ...
Yahoo4d
The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
Tirzepatide, the active ingredient in Zepbound and Mounjaro, is no longer in short supply, the FDA says. Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025 ...
Yahoo8d
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
The company's latest attempt at a weight loss drug, CagriSema, matched the bar set by a currently approved medicine but still didn't surpass it ... active ingredient tirzepatide, which mimics ...
Yahoo News4d
The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
Tirzepatide, the active ingredient in Zepbound and Mounjaro, is no longer in short supply, the FDA says. Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025.